• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

支气管镜介入治疗联合帕博利珠单抗治疗肺大细胞神经内分泌癌 1 例报告。

Bronchoscopic Interventional Therapy Combined With Pembrolizumab in the Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report.

机构信息

Department of Respiratory and Critical Care Medicine, Shengli Oilfield Central Hospital, Dongying, China.

Clinical Pharmacy of Pharmacy Department, Shengli Oilfield Central Hospital, Dongying, China.

出版信息

Clin Respir J. 2024 Sep;18(9):e70009. doi: 10.1111/crj.70009.

DOI:10.1111/crj.70009
PMID:39225701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11370624/
Abstract

This study reports a significant clinical outcome following the use of bronchoscopic interventional therapy combined with pembrolizumab for treating pulmonary large cell neuroendocrine carcinoma (LCNEC), showcasing a novel approach in managing this aggressive cancer.

摘要

本研究报告了经支气管镜介入治疗联合 pembrolizumab 治疗肺大细胞神经内分泌癌（LCNEC）的显著临床疗效，为治疗这种侵袭性癌症提供了一种新的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db74/11370624/3ce8498a7757/CRJ-18-e70009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db74/11370624/90b3570008b7/CRJ-18-e70009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db74/11370624/45a1b3fcb786/CRJ-18-e70009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db74/11370624/3ce8498a7757/CRJ-18-e70009-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db74/11370624/90b3570008b7/CRJ-18-e70009-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db74/11370624/45a1b3fcb786/CRJ-18-e70009-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db74/11370624/3ce8498a7757/CRJ-18-e70009-g001.jpg

相似文献

1
Bronchoscopic Interventional Therapy Combined With Pembrolizumab in the Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma: A Case Report.支气管镜介入治疗联合帕博利珠单抗治疗肺大细胞神经内分泌癌 1 例报告。
Clin Respir J. 2024 Sep;18(9):e70009. doi: 10.1111/crj.70009.
2
Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab.肺混合性大细胞神经内分泌癌经纳武利尤单抗治疗后长期生存。
Thorac Cancer. 2020 Jul;11(7):2036-2039. doi: 10.1111/1759-7714.13471. Epub 2020 May 7.
3
Large cell neuroendocrine carcinoma arising from the left main bronchus.起源于左主支气管的大细胞神经内分泌癌。
Intern Med. 2011;50(18):2003-6. doi: 10.2169/internalmedicine.50.5526. Epub 2011 Sep 15.
4
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.检查点抑制剂对高肿瘤突变负担的大细胞神经内分泌癌有效。
J Immunother Cancer. 2017 Sep 19;5(1):75. doi: 10.1186/s40425-017-0281-y.
5
Treatment options for patients with large cell neuroendocrine carcinoma of the lung.肺大细胞神经内分泌癌患者的治疗选择。
Gen Thorac Cardiovasc Surg. 2014 Jun;62(6):351-6. doi: 10.1007/s11748-014-0379-9. Epub 2014 Apr 10.
6
Combined large cell neuroendocrine carcinoma with giant cell carcinoma of the lungs: a case report.肺大细胞神经内分泌癌合并巨细胞癌 1 例报告。
World J Surg Oncol. 2013 Aug 19;11(1):205. doi: 10.1186/1477-7819-11-205.
7
[Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma].[肺大细胞神经内分泌癌的治疗进展]
Zhongguo Fei Ai Za Zhi. 2024 Aug 20;27(8):622-628. doi: 10.3779/j.issn.1009-3419.2024.102.28.
8
The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China.不同治疗方案的结果取决于肺大细胞神经内分泌癌的分子亚型：中国的一项回顾性研究。
Cancer Med. 2024 Jan;13(1):e6834. doi: 10.1002/cam4.6834. Epub 2024 Jan 5.
9
Combined large cell neuroendocrine carcinoma.混合性大细胞神经内分泌癌
Jpn J Thorac Cardiovasc Surg. 2004 Sep;52(9):426-8. doi: 10.1007/s11748-004-0037-8.
10
Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.铂类双联化疗联合阿替利珠单抗作为转移性大细胞神经内分泌癌一线治疗：单中心经验
Cancer Invest. 2022 Feb;40(2):124-131. doi: 10.1080/07357907.2021.1988962. Epub 2021 Oct 21.

本文引用的文献

1
[Clinical and molecular pathological features of bronchopulmonary large cell neuroendocrine carcinoma].支气管肺大细胞神经内分泌癌的临床及分子病理特征
Zhonghua Yi Xue Za Zhi. 2022 Apr 12;102(14):1020-1027. doi: 10.3760/cma.j.cn112137-20210814-01816.
2
[Progress of Immune Checkpoint Inhibitors 
in the Treatment of Advanced Pulmonary Neuroendocrine Tumors].免疫检查点抑制剂治疗晚期肺神经内分泌肿瘤的研究进展
Zhongguo Fei Ai Za Zhi. 2021 Nov 20;24(11):784-789. doi: 10.3779/j.issn.1009-3419.2021.102.42.
3
Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung.
免疫疗法在IV期肺大细胞神经内分泌癌中的作用。
Asian Pac J Cancer Prev. 2021 Feb 1;22(2):365-370. doi: 10.31557/APJCP.2021.22.2.365.
4
Immune Checkpoint Inhibitor Therapy Achieved Complete Response for Drug-Sensitive Mutation-Negative Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma with High Tumor Mutation Burden: A Case Report.免疫检查点抑制剂疗法对具有高肿瘤突变负荷的药物敏感型突变阴性转移性肺大细胞神经内分泌癌实现完全缓解：一例报告
Onco Targets Ther. 2020 Aug 19;13:8245-8250. doi: 10.2147/OTT.S259893. eCollection 2020.
5
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).分子亚型转移性大细胞神经内分泌癌（LCNEC）中 PD-L1 表达的流行率和预后价值。
Lung Cancer. 2019 Apr;130:179-186. doi: 10.1016/j.lungcan.2019.02.022. Epub 2019 Feb 21.
6
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.检查点抑制剂对高肿瘤突变负担的大细胞神经内分泌癌有效。
J Immunother Cancer. 2017 Sep 19;5(1):75. doi: 10.1186/s40425-017-0281-y.
7
[Interventional Bronchoscopies for the Treatment of 112 Cases with Complex Malignant Central Airway Diseases Involved in Bifurcation].[介入性支气管镜治疗累及分叉部的112例复杂恶性中央气道疾病]
Zhongguo Fei Ai Za Zhi. 2016 Dec 20;19(12):854-858. doi: 10.3779/j.issn.1009-3419.2016.12.08.